IMMUNOTECH-B Schedules 21 Aug 2026 Board Meeting to Approve 1H26 Interim Results

Bulletin Express

Aug 11

Immunotech Biopharm Ltd (IMMUNOTECH-B) has announced that its board of directors will convene on 21 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The meeting’s agenda includes consideration of the consolidated financial statements and related matters ahead of their planned publication.

The board is chaired by Executive Director Tan Zheng and comprises six non-executive directors—Yang Fan, Wang Ruihua, Wang Donghu, Yang Xin, Liu Rui and Cao Ran—alongside four independent non-executive directors: Professor Wang Yingdian, Ng Chi Kit, Peng Sujiu and Zhang Guoguang.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1194732077"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194732077\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194732077?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194732077","market":"us","top_or_hot":-1,"title":"IMMUNOTECH-B Schedules 21 Aug 2026 Board Meeting to Approve 1H26 Interim Results","media":"Bulletin Express","content":"<p>Immunotech Biopharm Ltd (IMMUNOTECH-B) has announced that its board of directors will convene on 21 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The meeting’s agenda includes consideration of the consolidated financial statements and related matters ahead of their planned publication.</p>\n<p>The board is chaired by Executive Director Tan Zheng and comprises six non-executive directors—Yang Fan, Wang Ruihua, Wang Donghu, Yang Xin, Liu Rui and Cao Ran—alongside four independent non-executive directors: Professor Wang Yingdian, Ng Chi Kit, Peng Sujiu and Zhang Guoguang.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNOTECH-B Schedules 21 Aug 2026 Board Meeting to Approve 1H26 Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNOTECH-B Schedules 21 Aug 2026 Board Meeting to Approve 1H26 Interim Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-11 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Immunotech Biopharm Ltd (IMMUNOTECH-B) has announced that its board of directors will convene on 21 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The meeting’s agenda includes consideration of the consolidated financial statements and related matters ahead of their planned publication.</p>\n<p>The board is chaired by Executive Director Tan Zheng and comprises six non-executive directors—Yang Fan, Wang Ruihua, Wang Donghu, Yang Xin, Liu Rui and Cao Ran—alongside four independent non-executive directors: Professor Wang Yingdian, Ng Chi Kit, Peng Sujiu and Zhang Guoguang.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06978","symbol_name":"永泰生物-B","start_time":0,"source_url":"","article_id":"1194732077","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194732077","pubTimestamp":1786453556,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Immunotech Biopharm Ltd (IMMUNOTECH-B) has announced that its board of directors will convene on 21 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06978":"永泰生物-B"},"translate_title":"IMMUNOTECH-B 计划于 2026 年 8 月 21 日召开董事会会议，批准 26 年上半年中期业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06978":1},"content_text":"Immunotech Biopharm Ltd (IMMUNOTECH-B) has announced that its board of directors will convene on 21 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The meeting’s agenda includes consideration of the consolidated financial statements and related matters ahead of their planned publication.\nThe board is chaired by Executive Director Tan Zheng and comprises six non-executive directors—Yang Fan, Wang Ruihua, Wang Donghu, Yang Xin, Liu Rui and Cao Ran—alongside four independent non-executive directors: Professor Wang Yingdian, Ng Chi Kit, Peng Sujiu and Zhang Guoguang.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}